Total Funding
17
48
Total FundingSeries C raised
Growth Score
0 pts
Heat Score
6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
21755
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.
Mark Sumeray: Chief Medical OfficerPast Role: Amryt Pharma, CMO
Louis J. Arcudi: Chief Financial OfficerPast Role: Peptimmune, Vice President of Finance and Administration and Treasurer
About the Company
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.
